[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100146936":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":32,"centralContacts":11,"locations":36,"responsibleParty":48,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence 1","EXPERIMENTAL",null,[13,14],"Drug: Treatment A","Drug: Treatment B",{"label":16,"type":10,"description":11,"interventionNames":17},"Sequence 2",[14,13],[19,24,28,30],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Treatment A","Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Treatment B","Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.",[9],{"type":20,"name":25,"description":26,"armGroupLabels":29,"otherNames":11},[16],{"type":20,"name":21,"description":22,"armGroupLabels":31,"otherNames":11},[16],[33],{"name":34,"affiliation":5,"role":35},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[37],{"facility":38,"status":11,"city":39,"state":11,"zip":40,"country":39,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":11},"Pfizer Investigational Site","Singapore","188770","SG",{"type":43,"coordinates":44},"Point",[45,46],103.85007,1.28967,{"lat":46,"lon":45},{"type":11,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":49,"oldOrganization":50},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100146936","phase-1-a-study-to-evaluate-the-effect-of-food-on-how-tasocitinib-cp-690550-is-absorbed-and-moves-through-the-body-following-oral-administration-of-tasocitinib-cp-690550-tablets-to-healthy-subjects-100146936",false,"NCT01184001","A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects","A Phase 1, Randomized, 2-Period, 2-Sequence, Open Label, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On Pharmacokinetics Of Tasocitinib (CP-690,550) Tablets In Healthy Subjects","Inclusion Criteria:\n\n* Healthy male and\u002For female (non-childbearing potential) subjects between the ages of 21 and 55 years.\n* Body Mass Index (BMI) of 17.5 to 30.5 kg\u002Fm2; and a total body weight for males\\>50 kg (110 lbs). For females, total body weight \\>45 kg (99 lbs).\n* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)\n\nExclusion Criteria:\n\n* Evidence or history of any clinically significant illness, medical condition, or disease.\n* Evidence or history of any clinically significant infections within the past 3 months.\n* Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.",true,"ALL","21 Years","55 Years",{"count":63,"type":64},16,"ACTUAL","INTERVENTIONAL",[67],"PHASE1","In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions. On one occasion the tasocitinib (CP-690,550) tablet will be administered in a fasting condition; On the other occasion the tasocitinib (CP-690,550) tablet will be administered in a fed condition following a standard breakfast meal. The amount of tasocitinib (CP-690,550) in the blood will be measured at various times over 24 hours following each dosing occasion and compared to evaluate for any differences.",[70],"Rheumatoid Arthritis",[72,73],"Healthy subjects","Food Effect Study","COMPLETED","2010-10-12",{"date":77,"type":78},"2010-10-13","ESTIMATED",{"date":80,"type":11},"2010-09",{"date":80,"type":64},{"name":5,"class":6},1]